Since 2012, Dr. Loretta Itri has served as the Executive Vice President of Global Health Sciences and Regulatory Affairs at a pharmaceutical company in New Jersey. Widely published in her field, Dr. Itri is the author of numerous papers on a wide range of topics in peer-reviewed journals. In particular, Loretta Itri, MD, has written on the topic of erythropoietin. Erythropoietin is a hormone made mainly by the kidneys in human beings. The hormone's primary function is to help produce red blood cells (erythrocytes), which are the main mechanism of transporting oxygen to the organs and tissues from the lungs. Dr. Itri and her co-authors demonstrated erythropoietin’s potential for safeguarding the human central nervous system against traumatic brain injury. The article detailed the encouraging results of a test in which the recombinant form of the hormone was injected directly into the ischemic (oxygen-deprived) brains of rodents. The premise of Dr. Itri's co-authored paper has been supported by a number of other studies since its publication.
0 Comments
|
AuthorAs chief medical officer and president of pharmaceutical development at a public biotech company, Dr. Loretta Itri oversaw the worldwide development of a number of important drugs, including Tesetaxel, a novel oral taxane used in the treatment of breast, gastric, and prostate cancer. Archives
October 2019
Categories |